The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Generalised Lipodystrophy, Partial Lipodystrophy
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
MEASuRE: Metreleptin Effectiveness And Safety Registry
-
University Alabama at Birmingham, Birmingham, Alabama, United States, 40506
City of Hope, Duarte, California, United States, 91010
Atlanta Diabetes Associates, Atlanta, Georgia, United States, 30318
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611
University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States, 66160
Children's Hospital of New Orleans/LSU Health Sciences Center, New Orleans, Louisiana, United States, 70118
Ochsner Clinic Foundation, New Orleans, Louisiana, United States, 70121
Nih/Niddk/Deob, Bethesda, Maryland, United States, 20892
University of Michigan, Ann Arbor, Michigan, United States, 48109
Childrens Hospital of Michigan, Detroit, Michigan, United States, 48201
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Aegerion Pharmaceuticals, Inc.,
Lori Hartnett, STUDY_DIRECTOR, Amryt Pharmaceuticals DAC
2031-10-31